BCL2 and breast carcinoma: For instance, miRNA-451 high expression sensitizes breast cancer cells to adriamycin,18 whereas upregulation of miRNA-21 promote cancer cell resistance to trastuzumab.19 In addition, high-expressed miR-125b confers the resistance of breast cancer cells to taxol through inhibition of Bcl-2 and Bak1 expression.20 Moreover, recent study reports that miRNA-205 enhances breast cancer cell resistance to doxorubicin and taxol by targeting VEGFA and FGF2.21